There’s no doubt that the Sunshine Act provisions of the Affordable Care Act, which require pharmaceutical companies to track and publicly report what they spend on U.S. healthcare providers, will make life more difficult for life sciences meeting planners. But it gets even more complicated when you take your meetings outside the U.S. and have to deal both with the rules of the event’s host country and those of your healthcare provider attendees.

As Peter Burberry, senior director, global practices for a U.S.-based specialty pharmaceutical company, said during his keynote address at the 2012 West Coast Life Sciences Meeting Management Forum in San Diego in December, planning meetings for pharma and medical device companies “is a whole different ballgame when you go global.” The event was co-organized by Medical Meetings magazine and The Center for Business Intelligence.